Parabilis Medicines, Inc. PBLS · SEC Filings

website

145

Parabilis Medicines, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell...

Price30.37

Market Cap3.7 B

Float82.07 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2026

News

TYPE

HEADLINE

FILED AT

8-K

Parabilis Medicines Enters into Third Amendment of Lease for Cambridge Headquarters and Expansion

Nov 5, 2026

8-K

Parabilis Medicines to Present Updated Clinical Data for Zolucatetide at ESMO Congress 2026

Sep 15, 2026

8-K

Parabilis Medicines, Inc. Announces Departure of Chief Medical Officer

Sep 2, 2026

8-K

Parabilis Medicines Appoints Oncology Drug Development Leader Craig L. Tendler, M.D., to Board of Directors

Aug 25, 2026

8-K

Parabilis Medicines Reports Q2 2026 Financial Results and Business Updates

Aug 13, 2026

8-K

Parabilis Medicines, Inc. Announces Private Placement with Regeneron Pharmaceuticals and Corporate Governance Updates

Jun 11, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B4

IPO | Offering amount: $670,000,000 | Shares: 33,500,000 | Price: $20.000 | Bank: Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities, LifeSci Capital

Jun 10, 2026

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 10, 2026

FWP

OFFERING - IPO | Bank: Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities, LifeSci Capital

Jun 9, 2026

S-1MEF

OFFERING

Jun 9, 2026

S-1/A

OFFERING - IPO | Bank: Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities, LifeSci Capital

Jun 9, 2026

8-A12B

Form 8-A12B - Registration of securities [Section 12(b)]

Jun 5, 2026

S-1/A

OFFERING - IPO | Bank: Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities, LifeSci Capital

Jun 4, 2026

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

Tendler Craig (Reporting)

Aug 25, 2026

Tendler Craig (Reporting)

Aug 25, 2026

SCHEDULE 13G

ARCH Venture Fund XII, L.P. (Filed by)

Aug 14, 2026

SCHEDULE 13G

FMR LLC (Filed by)

Aug 6, 2026

RA Capital Healthcare Fund LP (Reporting)

Jul 22, 2026

Soleus Capital, LLC (Reporting)

Jun 29, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 10, 2026